119 filings
Page 2 of 6
8-K
30kvzmfnnv5ql
16 May 23
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
4:24pm
8-K
73fha2u
4 May 23
Regulation FD Disclosure
4:07pm
8-K
nff bpe2cl0pjh
4 May 23
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
9:05am
8-K
sngrqtgpusk idr
4 May 23
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
6:42am
8-K
43stx9106t6vm1 jra5
21 Mar 23
Regulation FD Disclosure
5:02pm
8-K
t4jqtgif
21 Mar 23
X4 Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial
7:09am
8-K
3d0xr
10 Mar 23
Other Events
4:05pm
8-K
k256t
6 Jan 23
Entry into a Material Definitive Agreement
5:26pm
8-K
7c2uvh25
5 Jan 23
Regulation FD Disclosure
4:10pm
8-K
nol xwnt6p
23 Dec 22
Departure of Directors or Certain Officers
4:02pm
8-K
0djyy3o7 4u
9 Dec 22
X4 Pharmaceuticals Announces Proposed Public Offering
8:46am
8-K
yql2j26n395ovz477t
29 Nov 22
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
4:05pm
8-K
f0lp jcyl2wrfwhc
9 Nov 22
Departure of Directors or Certain Officers
4:18pm
8-K
51eoq3n qsbdnqcje4
3 Nov 22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:21am
8-K
o0xdnizjct qscrt
4 Oct 22
Regulation FD Disclosure
4:42pm
8-K
kycx760xz jfg25x0
27 Sep 22
Regulation FD Disclosure
7:53am
8-K
a4x2w1mdhq vhce
1 Sep 22
Material Modifications to Rights of Security Holders
4:51pm
8-K
pp2o0pim
5 Aug 22
Regulation FD Disclosure
8:10am
8-K
mftsyof3k9q0o 4v9
4 Aug 22
X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:29am
8-K
v87ptdjspjntayhom
29 Jul 22
Departure of Directors or Certain Officers
4:05pm